Digging through the Medicaid Prescription Drug Database, I want to find out if HIV drug prices are rising faster over time compared to other daily medications for chronic diseases. I stratified by the number of drugs in each combination tablet, and next I will need to adjust for inflation. Let me know if you think of a good class of comparator drugs.
SaveSave
Pulled from the Infectious Economics archives, these articles provide recommendations for the design and development of robust mathematical models of COVID-19 epidemiology and economics to reduce uncertainty in decision-making and inform evidence-based public policy. Associations are easy; valid causal inference is hard If we want to be honest in evaluating the winners and losers in…
The Irish Department of Health (DoH) is in the process of developing a national biosimilar medicines policy which aims to increase biosimilar use by creating a robust framework where biologicals and biosimilars can be used safely, cost-effectively, and confidently in the health service. In this example from an Irish teaching hospital, the introduction of the biosimilar first to new patients, along with a switching study executed in parallel, helped to raise prescriber confidence.
In this tutorial, you’ll gain access to the R code, dataset, and motivation to replicate data visualizations in my latest paper and apply the concepts to your next one. I sat on an airplane last year, flipping through The Economist, when I froze at the sight of a tiny chart littered with a mess of…
Lab coats are being ironed, promo stickers wrapped around candy bars, and strangers pulled off the street to help with utility testing. It’s time for the Business Plan Competition.
There is little prior evidence of effective interventions to improve viral suppression, despite this being a critical step in the HIV care continuum as described in the National HIV/AIDS Strategy for the United States.
Real world data from occupational safety programs revealed most Omicron cases were infectious for several days before being detectable by rapid antigen tests.
I think the difficulty is that we want to pay for drugs that innovate, and there’s been a lot of innovation in HIV medicines. Perhaps you could match HIV drugs with another class of drugs that has produced a similar amount of improvement in survival times in the same period. It’s hard to think of a class of drugs like that, but off the top of my head I might suggest drugs for CML or hepatitis C.